Centre for Biological Threats and Special Pathogens Project Groups and Junior Research Groups The Public Health Institute for Germany Head: Prof. Dr Lars Schaade Ω Science communication The Robert Koch Institute’s aim is to protect the population Ω Acinetobacter baumannii against disease and improve its state of health. To this end, Ω Health threats caused by highly pathogenic and relevant Ω Emerging zoonoses 1,400 individuals from 50 nations and 90 different occupa­ ­bioterrorist biological agents (microbes and toxins): Ω Epidemiological modelling of infectious diseases tional fields work together at RKI every day; around 600 of ­identification, assessment, management support Ω Systems-medicine of infectious disease them are scientists. They ­investigate the manifold impacts on Ω Federal Information Centre for Biological Threats and Ω Microbial Genomics (Junior Research Group) health and disease, draw up and verify evidence-based recom- ­Special Pathogens (IBBS) Ω Metabolism of microbial pathogens (Junior Research Group) mendations and develop new methods of health protection. Ω Cooperation with national and international partners in the field of biological security National Reference Centres and Consultant Laboratories Directorate Ω Diagnostics and rapid diagnostics at RKI Prof. Dr Lothar H. Wieler (President) Ω Providing support during international health emergencies Ω Bacillus anthracis Prof. Dr Lars Schaade (Vice President) Ω Research in diagnostics, epidemiology, pathogenesis and Ω Cryptococcosis and Rare Systemic Mycoses countermeasures of highly pathogenic agents Ω Electron Microscopic Diagnostics in Infectious Diseases Locations Ω Operating a biosafety level 4 laboratory (BSL-4) Ω Gonococci Ω Nordufer 20, 13353 Berlin-Wedding (main site) Ω Influenza Ω Seestraße 10, 13353 Berlin-Wedding Centre for International Health Protection Ω Listeria Ω General-Pape-Straße 62–66, 12101 Berlin-Tempelhof Head: Prof. Dr Johanna Hanefeld Ω Measles, Mumps, Rubella Ω Burgstraße 37, 38855 Wernigerode Ω Information Centre for International Health Protection: Ω Neurotoxin-producing Clostridia monitoring global health risks Ω Noroviruses Scientific Committees Ω Coordinating international projects such as the Global Ω Poxviruses Currently, 17 scientific committees that draw up recommenda- ­Health Protection Programme and the German Biosecurity Ω Poliomyelitis and Enteroviruses tions are based at RKI. They include the Standing Committee on Programme Ω Respiratory Syncitial Viruses, Parainfluenza, Metapneumo- Vaccination (STIKO) and the Commission for Hospital Hygiene Ω Development of evidence-based methods for international viruses and Infection Prevention (KRINKO). The committees are com- THE PUBLIC HEALTH INSTITUTE health protection Ω Rotaviruses posed of external experts in various disciplines. Ω Risk management and support, incl. training to prepare for Ω Salmonellosis and Other Enteric Pathogens The Robert Koch Institute international deployment and logistical support on the spot Ω Staphylococci and Enterococci Selected Publications Ω Setting up laboratory capacities and running courses for Ω Tularemia Ω Epidemiological Bulletin at a Glance ­laboratory staff abroad Ω Journal of Health Monitoring Ω Contact for the WHO Emergency Medical Teams Initiative WHO Reference Laboratories and Collaborating Centres Ω Epidemiological Yearbook of Notifiable Infectious Diseases Ω Regional WHO Reference Laboratory for Poliomyelitis Ω RKI fact sheets Ω Regional WHO Reference Laboratory for Measles and Rubella­ Ω Bundesgesundheitsblatt (co-editor) Ω WHO Collaborating Centre for Emerging Infections and Ω Publications in peer-reviewed scientific journals ­Biological Threats Ω WHO Collaborating Centre for the Global Outbreak Alert and Response Network (GOARN)

www.rki.de/en | [email protected] | Twitter @rki_de

The Robert Koch Institute is a Federal Institute ­within the

portfolio of the German Federal Ministry of Health · RKI, 2021 shutterstock/Daniel Fung Edgar Zippel; Peter Kuley/Wikimedia CC BA-SA 3.0; Manuel Frauendorf/skyfilmberlin; Images: RKI; Stephan Fiedler/Natascha Köbel;

Nordufer, Berlin Seestraße, Berlin General-Pape-Straße, Berlin Wernigerode Main Areas of Activity

Department of Infectious Diseases Department of Epidemiology and Health Monitoring Department of Infectious Disease Epidemiology Department of Methodology and Research Head: Prof. Dr Martin Mielke Head: N. N. Head: Dr Osamah Hamouda Infrastructure Head: Prof. Dr Lothar H. Wieler Public health microbiology Nationwide continuous health monitoring National surveillance of infectious diseases Ω Molecular epidemiology of pathogens, incl. resistance to Ω Representative health surveys (longitudinal and cross-sectional Ω Comprehensive reporting on notifiable infectious diseases Bioinformatics ­anti-infectives studies) of children, adolescents and adults in Germany: ­local Ω (Continued) development of surveillance systems, e.g. Ω development of new data analysis methods for high-through- Ω Pathogenic and resistance mechanisms; pathogen-host examinations ­sentinels put experiments, machine learning and data integration with ­interaction Ω Regular European Health Interview Surveys Ω Implementing the German electronic reporting and informa- applications in infection research, e.g. pathogen detection Ω Healthcare-associated infections and hospital hygiene Collecting health data on special sections of the population tion system for protection against infection, DEMIS and microbiome research Ω Diabetes surveillance Ω Prevention of healthcare-associated infections Infectious disease control Genome sequencing Ω Construction of a panel for immediate-response studies Ω Inactivation of infectious agents/tolerance Ω Advising public health services and the medical profession Ω central sequencing service implementing state-of-the-art Ω Viral infections Federal Health Reporting On-call service for infectious disease epidemiology Next-Generation Sequencing (NGS), adapting and establish- Ω Journal of Health Monitoring, including articles by RKI on Ω Point of contact for international bodies, e.g. ECDC and WHO ing it for time-independent, automated processing as well as Ω Viral infections in newborns and immunosuppressed public health topics analysing consistency and scalability for applications, e.g. for ­patients Investigation of national and international outbreaks Ω Regular, comprehensive reports on health in Germany the molecular surveillance of various infectious agents Ω HIV, retrovirology Ω Support in assessing, elucidating and managing outbreak Ω Influenza, SARS-CoV-2 and other respiratory viruses Epidemiological research events Central laboratory animal husbandry Ω Measles, mumps, rubella Ω Surveillance of non-communicable diseases and mental health Ω service facility for infection research involving laboratory Epidemiological research Ω Herpesviruses Ω Health and care of vulnerable groups, e.g. children and adoles- ­animals and animal-based experimental techniques Ω Vaccine-preventable diseases and vaccination rates Ω Poliovirus and other enteroviruses cents, elderly people, people from migrant backgrounds Ω Developing alternative and supplementary methods to Ω Sexually transmittable or bloodborne diseases Ω Gut-associated viruses (norovirus, rotavirus); ­ Ω Burden of disease ­animal experiments Ω Foodborne diseases hepatitis ­viruses (HEV) Ω Risk factors in common, non-communicable diseases, Ω Zoonoses Research data management e.g. physical activity, nutrition, social determinants Bacterial infections Ω Respiratory illnesses Ω management and publication of verified, cleaned research Ω Healthcare-associated infections and antimicrobial resistance German Centre for Cancer Registry Data Ω Antibiotic resistance and consumption data Ω Salmonella and other enteric pathogens (EHEC, Listeria) Ω Pooling and quality control of data from regional cancer Ω Developing and expanding RKI’s Research Data Centre Prevention strategie Ω Legionella ­registries Ω Studies on disease risk factors Ω Chlamydia and other sexually transmitted bacterial pathogens Ω Regular publication of a verified overall dataset Ω Development, communication and evaluation of evidence-­ Ω Analyses of cancer incidence, prevalence and survival Fungal, parasitic and mycotic infections based public health recommendations Ω Reporting on cancer in Germany Ω Diagnostics, therapy and prevention (toxoplasmosis, ­lamblia, Ω Contingency planning, including pandemic planning scabies, non-tuberculous mycobacteria) Network of public health players in Germany Training in infectious disease epidemiology Ω Diagnosis of invasive mycotic infections Ω Office of the ‘Zukunftsforum Public Health’ Ω Courses for public health professionals Persistent infectionsx Ω Postgraduate Training for Applied Epidemiology (PAE) Ω Master of Science in Applied Epidemiology (MSAE) with Charité – Universitätsmedizin Berlin